Biofrontera (BFRI) Registration Filing summary

Company overview and business model

• U.S.-based biopharmaceutical company focused on dermatological treatments, primarily photodynamic therapy (PDT) for actinic keratoses (AK), a pre-cancerous skin condition.

• Principal product is Ameluz®, used with RhodoLED® lamps for PDT; recently acquired all U.S. rights to Ameluz® and RhodoLED® from Biofrontera Group.

• Clinical pipeline includes label expansion for Ameluz® and new indications such as superficial basal cell carcinoma and moderate to severe acne.

• Divested Xepi® product line in Q4 2025 to focus on core dermatology business.

Financial performance and metrics

• History of operating losses and anticipates continued losses; may never achieve sustained profitability.

• Completed private placement of Series C Preferred Stock in two tranches, raising $11 million in 2025.

• Sale of Xepi® assets for up to $10 million, with $3 million paid upfront and additional milestone-based payments.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; proceeds from private placement used to fund acquisition of U.S. rights to Ameluz® and RhodoLED®.

• Intends to retain earnings for business development and does not plan to pay dividends in the foreseeable future.